Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		1 Months Ended	3 Months Ended
	Mar. 31, 2013 Segment Vendor	Mar. 31, 2013 Specialty pharmacy Customer	Aug. 31, 2012 Financing Agreement with Biopharma	Mar. 31, 2013 Minimum	Mar. 31, 2013 Maximum	Aug. 31, 2012 Maximum Financing Agreement with Biopharma
Accounting Policies [Line Items]
Additional cash and cash equivalents, description	We consider all highly liquid investments purchased with maturities of three months or less from the date of purchase to be cash equivalents.
Percentage of sales to one specialty pharmacy customer	98.50%
Number of customer		1
Number of manufacturer	1
Property and equipment, estimated useful life				3 years	5 years
Debt issuance date			Aug. 02, 2012
Proceeds from issuance of long-term obligation, net of cash paid for issuance costs			$ 30
Total amount to be paid related to debt						$ 45
Payment terms for discount on sales of Korlym sales	30 days
Product returns period prior to expiration date to provide credit	6 months
Product returns period after expiration date to provide credit	12 months
Number of operating segment	1
Probability percentage for achieving performance-based vesting criteria for expense recognition				70.00%